Trial Profile
Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Emtricitabine; Isoniazid; Lamivudine; Rifampicin; Tenofovir; Zidovudine
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 06 Aug 2018 Status changed from recruiting to completed, according to results published in the Clinical Infectious Diseases.
- 06 Aug 2018 Results published in the Clinical Infectious Diseases.
- 26 Jul 2017 Results of effects of efavirenz in women living with HIV (WLWH) during third trimester of pregnancy and post-partum (n=22) presented at the 9th International AIDS Society Conference on HIV Science